Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
This guidance recommends secukinumab for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
NICE’s guidance on TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383) also recommends TNF-alpha inhibitors, but for severe active ankylosing spondylitis. The difference results from the wording of the marketing authorisations for the drugs. The severity of disease in the clinical trials considered in both appraisals was similar and it is not intended that the recommendation in this guidance is for disease of lesser severity than in TA383.
Guidance development process
Next review: September 2019
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.